Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:APLIF NASDAQ:MYNZ NASDAQ:PRTG NASDAQ:RKDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLIFAppili Therapeutics$0.01$0.01$0.01▼$0.03$1.66M-0.5824,512 shsN/AMYNZMainz Biomed$1.82-8.1%$1.90$1.34▼$19.00$6.26M0.21146,022 shs113,807 shsPRTGPortage Biotech$5.97+4.4%$6.96$2.10▼$23.01$6.27M0.23988,273 shs9,203 shsRKDAArcadia Biosciences$4.63-2.3%$4.53$2.40▼$10.31$6.33M0.5309,067 shs12,365 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLIFAppili Therapeutics0.00%+16.10%+11.84%-37.73%-37.44%MYNZMainz Biomed+7.03%+36.55%+8.20%-38.13%-88.54%PRTGPortage Biotech-5.45%-3.54%-4.51%-15.26%+58.89%RKDAArcadia Biosciences-0.21%-0.21%-4.24%+50.00%+55.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLIFAppili Therapeutics0.112 of 5 stars0.03.00.00.00.00.80.0MYNZMainz Biomed2.3679 of 5 stars3.33.00.00.00.70.01.3PRTGPortage Biotech0.2441 of 5 stars0.02.00.00.03.30.00.0RKDAArcadia Biosciences2.4004 of 5 stars3.53.00.00.04.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLIFAppili Therapeutics 0.00N/AN/AN/AMYNZMainz Biomed 2.50Moderate Buy$14.00669.23% UpsidePRTGPortage Biotech 0.00N/AN/AN/ARKDAArcadia Biosciences 3.00Buy$6.0029.59% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLIFAppili Therapeutics$70K23.73N/AN/A($0.08) per share-0.17MYNZMainz Biomed$890K7.03N/AN/A$2.61 per share0.70PRTGPortage BiotechN/AN/A$7.96 per share0.75$3.74 per shareN/ARKDAArcadia Biosciences$5.26M1.20N/AN/A$4.56 per share1.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLIFAppili Therapeutics-$1.89M-$0.01N/A∞N/AN/AN/A-118.77%N/AMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/APRTGPortage Biotech-$75.34M-$41.65N/A∞N/AN/AN/AN/A8/26/2025 (Estimated)RKDAArcadia Biosciences-$7.04M-$4.28N/A∞N/A-38.34%-16.94%-10.56%8/12/2025 (Estimated)Latest APLIF, MYNZ, RKDA, and PRTG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RKDAArcadia Biosciences-$0.98$1.90+$2.88$1.90$1.60 million$1.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLIFAppili TherapeuticsN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/APRTGPortage BiotechN/AN/AN/AN/AN/ARKDAArcadia BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLIFAppili TherapeuticsN/A0.190.19MYNZMainz Biomed0.141.321.26PRTGPortage BiotechN/AN/AN/ARKDAArcadia BiosciencesN/A3.993.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLIFAppili TherapeuticsN/AMYNZMainz BiomedN/APRTGPortage Biotech13.36%RKDAArcadia Biosciences17.73%Insider OwnershipCompanyInsider OwnershipAPLIFAppili Therapeutics11.84%MYNZMainz BiomedN/APRTGPortage BiotechN/ARKDAArcadia Biosciences1.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLIFAppili Therapeutics8121.27 million106.91 millionNot OptionableMYNZMainz Biomed303.44 millionN/ANot OptionablePRTGPortage Biotech61.05 millionN/AOptionableRKDAArcadia Biosciences601.37 million1.34 millionNot OptionableAPLIF, MYNZ, RKDA, and PRTG HeadlinesRecent News About These CompaniesRKDA Arcadia Biosciences, Inc.May 24, 2025 | seekingalpha.comArcadia Biosciences, Inc. (RKDA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comARCADIA BIOSCIENCES Earnings Results: $RKDA Reports Quarterly EarningsMay 10, 2025 | nasdaq.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comArcadia Biosciences Inc (RKDA) Q1 2025 Earnings Call Highlights: Strong Zola Sales and ...May 9, 2025 | finance.yahoo.comArcadia Biosciences, Inc.: Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | finanznachrichten.deArcadia Climbs on Q1 FiguresMay 8, 2025 | baystreet.caArcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | uk.finance.yahoo.comArcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | globenewswire.comArcadia Biosciences Q1 Earnings PreviewMay 7, 2025 | msn.com5RKDA : What's Next: Arcadia Biosciences's Earnings PreviewMay 7, 2025 | benzinga.comArcadia Biosciences, Inc. Announces Q1 2025 Financial Results Release and Conference Call ScheduleApril 29, 2025 | quiverquant.comQArcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference CallApril 29, 2025 | globenewswire.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2024 Earnings Call TranscriptMarch 22, 2025 | msn.comArcadia Biosciences outlines 2025 growth potential for Zola after 46% sales increase in 2024March 21, 2025 | msn.comArcadia Biosciences, Inc (RKDA) Q4 2024 Earnings Call TranscriptMarch 20, 2025 | seekingalpha.comArcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business HighlightsMarch 20, 2025 | businesswire.comArcadia Biosciences Q4 Earnings PreviewMarch 19, 2025 | msn.comArcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2024 Financial Results and Business Highlights Conference CallMarch 6, 2025 | businesswire.comRKDA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Arcadia Biosciences, Inc. is Fair to ShareholdersFebruary 24, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPLIF, MYNZ, RKDA, and PRTG Company DescriptionsAppili Therapeutics OTCMKTS:APLIF$0.01 0.00 (0.00%) As of 07/15/2025Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.Mainz Biomed NASDAQ:MYNZ$1.82 -0.16 (-8.08%) Closing price 04:00 PM EasternExtended Trading$1.87 +0.05 (+2.75%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Portage Biotech NASDAQ:PRTG$5.97 +0.25 (+4.37%) Closing price 04:00 PM EasternExtended Trading$5.80 -0.18 (-2.93%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.Arcadia Biosciences NASDAQ:RKDA$4.64 -0.10 (-2.19%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
